Effects of antiresorptive therapies on glucose metabolism: Results from the FIT, HORIZON-PFT, and FREEDOM trials
The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
In rodent models, undercarboxylated osteocalcin (ucOC) acts as a hormone that promotes insulin sensitivity and secretion. If ucOC plays a similar role in humans, then antiresorptive therapies, which reduce ucOC levels, may increase the risk of insulin resistance and diabetes. We tested whether antiresorptive therapies result in higher fasting glucose, increased weight, or greater diabetes incidence in post hoc analyses of three randomized, placebo-controlled trials in postmenopausal women: Fracture Intervention Trial (FIT) (N = 6151) of alendronate (4 years), Health Outcomes and Reduced Incidence with Zoledronic Acid Once Yearly Pivotal Fracture Trial (HORIZON-PFT) (N = 7113) of zoledronic acid (3 years), and Fracture Reduction Evaluation of Denosumab in Osteoporosis Every 6 Months (FREEDOM) trial (N = 7076) of denosumab (3 years). Fasting glucose was measured annually in FIT and HORIZON in a subset of women, and every 6 months in FREEDOM in all participants. Weight was measured annually in all trials. Incident diabetes was identified from adverse event reports, initiation of diabetes medication, or elevated fasting glucose. Differences in fasting glucose changes from randomization to trial conclusion between treatment and placebo groups were not statistically significant: −0.47 mg/dL in FIT, 0.20 mg/dL in HORIZON-PFT, and 0.09 mg/dL in FREEDOM, all p > 0.6. Weight change differed between treatment and placebo groups in FIT (0.32 kg, p = 0.003) and FREEDOM (0.31 kg, p = 0.023) but not in HORIZON-PFT (0.15 kg, p = 0.132). In the three trials combined, diabetes occurred in 203 and 225 women assigned to treatment or placebo, respectively. Diabetes incidence was not increased in any of the treatment groups or in the pooled estimate (pooled relative risk [RR] = 0.90; 95% confidence interval [CI] 0.74–1.10). Antiresorptive therapy does not have a clinically important effect on fasting glucose, weight, or diabetes risk in postmenopausal women. Contrary to predictions from mouse models, reduced bone turnover does not appear to play a significant role in glucose metabolism in humans.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Black, D. M., Cummings, S. R., Karpf, D. B., Cauley, J. A., Thompson, D. E., Nevitt, M. C., Bauer, D. C., Genant, H. K., Haskell, W. L., Marcus, R., et al. (1996) · The Lancet · doi:10.1016/s0140-6736(96)07088-2 · Cited by 3,846
Self-citationDenosumab for Prevention of Fractures in Postmenopausal Women with Osteoporosis
Cummings, S. R., Martin, J. S., McClung, M. R., Siris, E. S., Eastell, R., Reid, I. R., Delmas, P., Zoog, H. B., Austin, M., Wang, A., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0809493 · Cited by 3,489
Self-citationOnce-Yearly Zoledronic Acid for Treatment of Postmenopausal Osteoporosis
Black, D. M., Delmas, P. D., Eastell, R., Reid, I. R., Boonen, S., Cauley, J. A., Cosman, F., Lakatos, P., Leung, P. C., Man, Z., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa067312 · Cited by 2,986 · cited 2×
“In HORIZON, 7736 postmenopausal women aged 65 to 89 years were stratified into two groups based on current use of other osteoporosis medications and were randomized within the two strata to receive a once-yearly infusion (5mg) of zoledronic acid (ZOL) or placebo for up to 3 years.((19)) All women also received oral da…”
BackgroundMethodSelf-citationEndocrine regulation of energy metabolism by the skeleton
Lee, N. K., Sowa, H., Hinoi, E., Ferron, M., Ahn, J. D., Confavreux, C., Dacquin, R., Mee, P. J., McKee, M. D., Jung, D. Y., et al. (2007) · Cell · doi:10.1016/j.cell.2007.05.047 · Cited by 2,554
Cummings, S. R. (1998) · JAMA · doi:10.1001/jama.280.24.2077 · Cited by 2,277
Self-citationInsulin signaling in osteoblasts integrates bone remodeling and energy metabolism
Ferron, M., Wei, J., Yoshizawa, T., Del Fattore, A., DePinho, R. A., Teti, A., Ducy, P., & Karsenty, G. (2010) · Cell · doi:10.1016/j.cell.2010.06.003 · Cited by 1,123 · cited 3×
“Findings in rodent models indicate that osteocalcin (OC) acts as a hormone that promotes insulin sensitivity in peripheral tissues and insulin secretion by the pancreas.((1,2)) OC knock-out mice have increased fat mass and insulin resistance, and are more likely than wild-type littermates to develop diabetes on a high…”
BackgroundResultFerron, M., Hinoi, E., Karsenty, G., & Ducy, P. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0711119105 · Cited by 900 · cited 1×
“At the same time, the findings from rodent models, if proven in humans, suggest new possibilities for the prevention of insulin resistance and diabetes through alterations in bone metabolism.((9)) OC levels are lower in thosewith diabetes in cross-sectional studies, but thismay be because of negative effects of diabet…”
BackgroundEpidemiologic trends in overweight and obesity
Ogden, C. L., Carroll, M. D., & Flegal, K. M. (2003) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/s0889-8529(03)00074-4 · Cited by 282 · cited 2×
“The women in these trials were recruited on the basis of osteoporosis, associated with lower weight, and the prevalence of overweight and obesity in the trials was lower than in broader populations of a similar age.((27)) Thus, trial participants may have had a lower risk of developing diabetes than the general popula…”
ResultEffect of Vitamin K Supplementation on Insulin Resistance in Older Men and Women
Yoshida, M., Jacques, P. F., Meigs, J. B., Saltzman, E., Shea, M. K., Gundberg, C., Dawson-Hughes, B., Dallal, G., & Booth, S. L. (2008) · Diabetes Care · doi:10.2337/dc08-1204 · Cited by 177 · cited 1×
“These trials reported no effect on fasting glucose or insulin resistance over 1 year((34)) and 3 years.((12))”
Background
Cited by
Qaseem, A., Forciea, M. A., McLean, R. M., Denberg, T. D., & for the Clinical Guidelines Committee of the American College of Physicians* (2017) · Annals of Internal Medicine · doi:10.7326/m15-1361 · Cited by 676
New insights into the biology of osteocalcin
Zoch, M. L., Clemens, T. L., & Riddle, R. C. (2016) · Bone · doi:10.1016/j.bone.2015.05.046 · Cited by 611
Zoccali, C., Vanholder, R., Massy, Z. A., Ortiz, A., Sarafidis, P., Dekker, F. W., Fliser, D., Fouque, D., Heine, G. H., Jager, K. J., et al. (2017) · Nature Reviews Nephrology · doi:10.1038/nrneph.2017.52 · Cited by 444
The Relevance of Mouse Models for Investigating Age-Related Bone Loss in Humans
Jilka, R. L. (2013) · The Journals of Gerontology Series A: Biological Sciences and Medical Sciences · doi:10.1093/gerona/glt046 · Cited by 329
The role of osteoblasts in energy homeostasis
Dirckx, N., Moorer, M. C., Clemens, T. L., & Riddle, R. C. (2019) · Nature Reviews Endocrinology · doi:10.1038/s41574-019-0246-y · Cited by 292
Metadata
- Authors
- Schwartz, A. V., Schafer, A. L., Grey, A., Vittinghoff, E., Palermo, L., Lui, L.-Y. L., Wallace, R. B., Cummings, S. R., Black, D. M., Bauer, D. C., & Reid, I. R.
- Venue
- Journal of Bone and Mineral Research
- Publisher
- Oxford University Press (OUP)
- Published
- 2013-01-15
- Volume
- 28
- Issue
- 6
- Pages
- 1348-1354
- ISSN
- 0884-0431 (ISSN-L)
- 1523-4681
- OpenAlex
- W1501939485
- Cited by
- 134
- References
- 9
- FWCI
- 16.94
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Effects of antiresorptive therapies on glucose metabolism: Results from the FIT, HORIZON-PFT, and FREEDOM trials. https://app.cochat.ai/papers/10.1002/jbmr.1865
- The paper
- Schwartz, A. V., Schafer, A. L., Grey, A., Vittinghoff, E., Palermo, L., Lui, L.-Y. L., Wallace, R. B., Cummings, S. R., Black, D. M., Bauer, D. C., & Reid, I. R. (2013). Effects of antiresorptive therapies on glucose metabolism: Results from the FIT, HORIZON-PFT, and FREEDOM trials. Journal of Bone and Mineral Research. https://doi.org/10.1002/jbmr.1865
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.